Company Profile

Xeris Pharmaceuticals Stock Price, News & Analysis

United StatesBiotechnologyNASDAQ

Company overview

Business overview

Xeris Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NASDAQ, Xeris Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.

Business Model Characteristics

Xeris Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.

Position Within the Biotechnology Landscape

Compared with more mature healthcare names, Xeris Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.

Why the stock is moving

XERS is trading with a steady catalyst profile while investors wait for the next headline that changes the story.

Future catalysts

Xeris’s catalysts are Recorlev, Gvoke, and the company’s endocrinology portfolio. Investors will watch whether the commercial base keeps broadening beyond a single product story.

Recent news

The five most recent feed items are shown below in reverse chronological order.

  1. 01

    Xeris Biopharma Reports First Quarter 2026 Financial Results

    Source: Xeris Pharmaceuticals

  2. 02
  3. 03

    Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025

    Source: Xeris Pharmaceuticals

  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.